These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8422185)

  • 1. [New anthracyclines].
    Ogawa M; Ariyoshi Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):27-33. PubMed ID: 8422185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW; Raymond V
    Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
    [No Abstract]   [Full Text] [Related]  

  • 3. [New anthracycline analogues in the treatment of lung cancer].
    Ueoka H; Ohnoshi T; Kimura I
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2146-9. PubMed ID: 1332624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
    Hurteloup P; Ganzina F
    Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anthracycline antitumor antibiotics.
    Muggia FM; Green MD
    Crit Rev Oncol Hematol; 1991; 11(1):43-64. PubMed ID: 1831987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current status of clinical results of new antitumor drugs].
    Ogawa M
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):179-88. PubMed ID: 3918502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Johnson RK; Ovejera AA; Goldin A
    Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
    [No Abstract]   [Full Text] [Related]  

  • 10. Anthrapyrazoles: true successors to the anthracyclines?
    Judson IR
    Anticancer Drugs; 1991 Jun; 2(3):223-31. PubMed ID: 1802016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I clinical study of MX2 (KRN 8602)].
    Majima H
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):359-64. PubMed ID: 2310202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
    Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
    Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
    [No Abstract]   [Full Text] [Related]  

  • 13. Idarubicin: a brief overview on pharmacology and clinical use.
    Borchmann P; Hübel K; Schnell R; Engert A
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):80-3. PubMed ID: 9147715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
    Speth PA; Minderman H; Haanen C
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):2-9. PubMed ID: 2648580
    [No Abstract]   [Full Text] [Related]  

  • 15. [Antitumor candidate compounds under clinical trials in Japan].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):342-51. PubMed ID: 1689987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
    Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice.
    Yoshida M; Fujioka A; Nakano K; Yuasa C; Toko T; Takeda S; Unemi N
    Anticancer Res; 1996; 16(5A):2875-9. PubMed ID: 8917401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
    Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
    Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical pharmacology of idarubicin].
    Robak T
    Acta Haematol Pol; 1993; 24(4):315-26. PubMed ID: 8303977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.